Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by DryBoneson Mar 24, 2020 4:20pm
101 Views
Post# 30843138

The market is up today,

The market is up today, While Liminal has gone subliminal.  This is a sign that the whole dang market now knows the true prospects of LMNL.  The truth has been concealed for a long long time.  Have even the Tommies have stoppped trying to manipulate the market up and to try to preserve some semblence of value where there is little or nearly none?  

Look at the probable failures, the prospects are dismal and dimming further everyday:
1.  Can they produce bio-pure Ryplazim for the FDA trials?  Probably not.
2. Can they fix the quality control problem.  Probably not.
3.  The market for Ryplazim may be too small or non-existent.  All too probable.
4.  They lack the resources for the other orphan indications clinical trials.  Very probable.
5.  The bio-separation business had to be sold because it didn't perform.  Most likely true.
6.  It is doubtful they will be able to partner.  They have failed at this for years and years already.

The likelyhood is that they will have to sell the company to a real player that has the resources and scientific expertise to deliver.

On the other hand.  KEEP BUYING MARC JONSTON AND NEW CAMEO.  YOU ARE DOING A WONDERFUL JOB.
<< Previous
Bullboard Posts
Next >>